Interest of High-speed Centrifugation for Measuring Anti-Xa Activity on Lipemic Plasma
University Hospital, Strasbourg, France
150 participants
Mar 11, 2024
OBSERVATIONAL
Conditions
Summary
Some hemostasis techniques require spectrophotometric measurements. These are then subject to interference from the sample's lipemia (postprandial, hypertriglyceridemia, etc.), which risks distorting the results; this is estimated to affect 0.5 to 2.5% of samples. This is particularly the case for anti-Xa activity, a critical test used to monitor anticoagulant treatments. To date, the HUS Hematology Laboratory does not have or is aware of any alternative method to overcome this interference, and is unable to perform anti-Xa activity when the sample has excessive lipemia. This study will evaluate, on samples from routine care artificially overloaded with lipids, the effectiveness of a high-speed centrifugation process (10,800g for 10 minutes).
Eligibility
Inclusion Criteria3
- Adult patient (≥ 18 years)
- Patient anticoagulated with an anti-Xa (UFH, LMWH, fondaparinux, danaparoid, apixaban, rivaroxaban)
- Sample sent to the HUS Hematology Laboratory and analyzed for measurement of the anti-Xa activity of an anticoagulant as part of routine care
Exclusion Criteria2
- Patient with a basal lipidemic sample
- Sample of insufficient volume
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07200674